When tumour tissue is unavailable, cell-free DNA (cfDNA)can serve as a surrogate for genetic analyses. Because mutated alleles in cfDNA are usually below 1%, next-generation sequencing (NGS)must be narrowed to target only clinically relevant genes. In this proof-of-concept study, we developed a panel to use in ultra-deep sequencing to identify such mutations in cfDNA.
Development of a gene panel for next-generation sequencing of clinically relevant mutations in cell-free DNA from cancer patients / Malapelle, Umberto; Mayo de Las Casas, Clara; Rocco, Danilo; Garzon, Monica; Pisapia, Pasquale; Jordana Ariza, Nuria; Russo, Maria; Sgariglia, Roberta; DE LUCA, Caterina; Pepe, Francesco; Martinez Bueno, Alejandro; Morales Espinosa, Daniela; González Cao, María; Karachaliou, Niki; Viteri Ramirez, Santiago; Bellevicine, Claudio; Molina Vila, Miguel Angel; Rosell, Rafael; Troncone, Giancarlo. - In: BRITISH JOURNAL OF CANCER. - ISSN 0007-0920. - (2017). [10.1038/bjc.2017.8]
Development of a gene panel for next-generation sequencing of clinically relevant mutations in cell-free DNA from cancer patients
MALAPELLE, UMBERTO;Pisapia, Pasquale;RUSSO, MARIA;SGARIGLIA, ROBERTA;DE LUCA, CATERINA;PEPE, FRANCESCO;BELLEVICINE, CLAUDIO;TRONCONE, GIANCARLO
2017
Abstract
When tumour tissue is unavailable, cell-free DNA (cfDNA)can serve as a surrogate for genetic analyses. Because mutated alleles in cfDNA are usually below 1%, next-generation sequencing (NGS)must be narrowed to target only clinically relevant genes. In this proof-of-concept study, we developed a panel to use in ultra-deep sequencing to identify such mutations in cfDNA.I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
